{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:24:29Z","timestamp":1760783069152,"version":"3.35.0"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,6,28]],"date-time":"2008-06-28T00:00:00Z","timestamp":1214611200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:p>Etanercept is a tumor necrosis factor (TNF) blocking agent that has been shown to suppress ongoing experimental autoimmune myasthenia gravis (EAMG). This subcutaneously administered TNF blocking agent has also been shown to be safe and effective in several rheumatological diseases including rheumatoid arthritis, psoriasis, and ankylosing spondylitis. A prospective clinical pilot trial of etanercept in corticosteroid\u2010dependent autoimmune myasthenia gravis (MG) patients supports further study into etanercept as a treatment for MG.<\/jats:p>","DOI":"10.1196\/annals.1405.028","type":"journal-article","created":{"date-parts":[[2008,6,20]],"date-time":"2008-06-20T23:23:28Z","timestamp":1214004208000},"page":"300-304","source":"Crossref","is-referenced-by-count":19,"title":["<i>Etanercept Treatment in Myasthenia Gravis<\/i>"],"prefix":"10.1111","volume":"1132","author":[{"given":"Julie","family":"Rowin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,6,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2006.00605.x"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-829586"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.1.35"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-12-199312150-00007"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6.1778"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.2.258"},{"key":"e_1_2_8_8_2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall R.S.A.","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1212\/WNL.56.1.97","article-title":"Mycophenolate mofetil for myasthenia gravis: an open\u2010label pilot study","volume":"56","author":"Ciafaloni E.","journal-title":"Neurology"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.064"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000094122.88929.0B"},{"key":"e_1_2_8_12_2","doi-asserted-by":"crossref","DOI":"10.1196\/annals.1405.031","article-title":"Lessons from two trials of mycophenolate mofetil in myasthenia gravis","author":"Sanders D.B.","year":"2008","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.031"},{"issue":"2","key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.62.suppl_2.ii13","article-title":"Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis","volume":"62","author":"Hochberg M.C.","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(92)90057-L"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340908"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340908"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00181-6"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(96)00152-X"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(96)00197-X"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(01)00473-8"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4598(199705)20:5<543::AID-MUS2>3.0.CO;2-9"},{"key":"e_1_2_8_23_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJM199707173370301","article-title":"Treatment of rheumatoid arthritis with a recombinant tumor necrosis factor receptor (p75)\u2010Fc fusion protein","volume":"337","author":"Moreland L.W.","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_8_24_2","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized controlled trial","volume":"130","author":"Moreland L.W.","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11017"},{"key":"e_1_2_8_26_2","first-page":"1238","article-title":"Long\u2010term safety and efficacy of etanercept in patients with rheumatoid arthritis","volume":"28","author":"Moreland L.W.","year":"2001","journal-title":"J. Rheumatol."},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00004"},{"issue":"5","key":"e_1_2_8_28_2","first-page":"A185","article-title":"A pilot trial of etanercept in the treatment of steroid\u2010dependent, generalized autoimmune myasthenia gravis","volume":"62","author":"Rowin J.","year":"2004","journal-title":"Neurology"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb11015.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.057"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1254.057"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.06.002"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.01.013"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1405.028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1405.028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:14:40Z","timestamp":1738268080000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1405.028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1196\/annals.1405.028"],"URL":"https:\/\/doi.org\/10.1196\/annals.1405.028","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"type":"print","value":"0077-8923"},{"type":"electronic","value":"1749-6632"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}